Indi Molecular scores first funding round

Chemical & Engineering News (June 30, 2017) [Read more…] … [Read more]

Indi Molecular Building Discovery Platform With Fresh Series A Financing

360Dx / GenomeWeb (June 30, 2017) [Read more…] … [Read more]

Indi Molecular Raises $11.5 in Series A Round

BioCentury (June 29, 2017) [Read more…] … [Read more]

Indi Molecular raises $11.5M in series A to back new synthetic class in research, imaging

BioWorld Medtech (June 29, 2017) [Read more…] … [Read more]

Indi Molecular Raises $11.5M Series A to Accelerate PCC Platform Development

CULVER CITY, CA – June 28, 2017 – Indi Molecular, an emerging life sciences company that is developing a novel, synthetic class of binders with antibody-like properties called protein catalyzed capture agents (PCCs), announced today that it has … [Read more]

Angewandte Chemie Paper Demonstrates PCC Ability to Enter Cells and Inhibit Botulinum Neurotoxin with Remarkable Binding Ability and Specificity

Angewandte Chemie (April 29, 2015) [Read more…] … [Read more]

Landmark Indi Molecular® Publication in Nature Chemistry Suggests PCC Binding Technology May Enable Therapeutics for Previously Undruggable Targets Based on Mutations of A Single Amino Acid

CULVER CITY, CA – (April 13, 2015) – Researchers at Caltech and Indi Molecular announced today a landmark publication in Nature Chemistry suggesting that the PCC (protein catalyzed capture) agent binding technology may enable the creation of highly … [Read more]

GenomeWeb – Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics

GenomeWeb | Dec 19, 2014 | Adam Bonislawski "As we have talked to pharmaceutical companies, it has become very clear that their interest is in super-binding molecules that can target very low abundance therapeutic targets, things that are really … [Read more]

Indi Molecular® and Sigma-Aldrich® Establish Collaboration to Explore Use of PCC Technology in Biological Tools

Press Release | 17 December 2014 CULVER CITY, CA -- Indi Molecular, the maker of a synthetic replacement for monoclonal antibodies, today announced that it has entered into a co-development agreement with Sigma-Aldrich to explore the use of Indi … [Read more]

Dr. Doug Fisher to Speak at Life Sciences Summit

Dr. Doug Fisher, to Speak at Life Sciences Summit October 29, 2014 | New York, NY | www.lifesciencessummit.org … [Read more]